Investigational drug · Phase 2
Volixibat
Also called: SHP626
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, PBC.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "Volixibat"
First trial start
2020
Dec 18, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Volixibat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Sclerosing Cholangitis
- Primary Biliary Cholangitis
- PBC
Approved drugs for the same conditions: Primary biliary cholangitis · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Volixibat" as an intervention, largest first.
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisPivotal-lookingActive, not recruiting
Mirum Pharmaceuticals, Inc.Industry
NCT05050136 · 333 participants · Start Sep 22, 2021 · Primary completion Jan 2027
Drug: Volixibat; Placebo · For: Primary Biliary Cholangitis; PBC
Sites: Coronado, California; Los Angeles, California; Sacramento, California · 130 sites in all
- Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)Pivotal-lookingTerminated
Mirum Pharmaceuticals, Inc.Industry
NCT02787304 · 197 participants · Start Oct 24, 2016 · Primary completion Jul 27, 2018
Drug: SHP626; Placebo · For: Non-Alcoholic Steatohepatitis
Sites: Coronado, California; Fresno, California; Los Angeles, California · 65 sites in all
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)Pivotal-lookingActive, not recruiting
Mirum Pharmaceuticals, Inc.Industry
NCT04663308 · 182 participants · Start Dec 18, 2020 · Primary completion Feb 20, 2026
Drug: Volixibat; Placebo · For: Primary Sclerosing Cholangitis
Sites: Coronado, California; Los Angeles, California; Sacramento, California · 103 sites in all
Mirum Pharmaceuticals, Inc.Industry
NCT02287779 · 84 participants · Start Jan 19, 2015 · Primary completion Jun 19, 2015
Drug: SHP626; Placebo · For: Non-Alcoholic Steatohepatitis
Sites: Knoxville, Tennessee
Mirum Pharmaceuticals, Inc.Industry
NCT02475317 · 84 participants · Start Jun 1, 2015 · Primary completion Dec 1, 2015
Drug: Placebo; Maralixibat and 1 more · For: Healthy Volunteers
Sites: Knoxville, Tennessee
- A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One DoseCompleted
Mirum Pharmaceuticals, Inc.Industry
NCT02571192 · 8 participants · Start Oct 1, 2015 · Primary completion Oct 1, 2015
Drug: SHP626 · For: Non-Alcoholic Steatohepatitis
Sites: Madison, Wisconsin
Mirum Pharmaceuticals, Inc.Industry
NCT04718961 · 4 participants · Start Jan 4, 2021 · Primary completion Dec 7, 2022
Drug: Volixibat; Placebo · For: Intrahepatic Cholestasis of Pregnancy
Sites: Birmingham, Alabama; New Haven, Connecticut; Miami, Florida · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- New and emerging treatments for PBC-related pruritus.
Anderson SL · Drugs Context 2026
- Efficacy, Safety and Tolerability of Volixibat, an IBAT Inhibitor, in Patients With Intrahepatic Cholestasis of Pregnancy.
Ovadia C, Stone S, Sibai B, et al. · Liver Int 2026
- Volixibat Leads to Improvements in Fatigue and Sleep for Adults With PBC: Data From VANTAGE.
· Gastroenterol Hepatol (N Y) 2025
- Intrahepatic Cholestasis of Pregnancy: Diagnosis, Management, and Future Directions-A Review of the Literature.
Jasak K, Gajzlerska-Majewska W, Jabiry-Zieniewicz Z, et al. · Diagnostics (Basel) 2025
- Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
Newsome PN, Palmer M, Freilich B, et al. · J Hepatol 2020
- [The inhibitors of the apical sodium-dependent bile acid transporter (ASBT) as promising drugs].
Saveleva EE, Tyutrina ES, Nakanishi T, et al. · Biomed Khim 2020
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.